Xencor | XNCR - Selling And Administration Expenses



Xencor reported $15.11M in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.


Selling And Administration Expenses Change Date
AbbVie USD 3.25B 40M Jun/2025
Alnylam Pharmaceuticals USD 323.31M 83.36M Jun/2025
Amgen USD 1.69B 4M Jun/2025
Arrowhead Research USD 30.95M 3.06M Jun/2025
AstraZeneca USD 5.01B 1.42B Jun/2025
Biogen USD 583.8M 11.3M Jun/2025
Bristol-Myers Squibb USD 1.71B 129M Jun/2025
Cytokinetics USD 65.72M 8.35M Jun/2025
GlaxoSmithKline GBP 2.14B 80M Jun/2025
J&J USD 5.89B 777M Jun/2025
MacroGenics USD 9.3M 18.51M Jun/2025
Merck USD 2.63B 104M Jun/2025
Novartis USD 3.44B 384M Jun/2025
Pfizer USD 3.42B 406M Jun/2025
Regeneron Pharmaceuticals USD 634.2M 1.2M Jun/2025
Roche Holding CHF 3.61B 381M Dec/2024
Xencor USD 15.11M 2.22M Jun/2025